Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Coacillium
Therapeutic Area : Dermatology
Study Phase : Phase II/ Phase III
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : LH-8 (coacillium) is an investigational botanical drug and is the first and only drug candidate for alopecia areata in children and adolescents with both moderate and severe forms of the disease.
Brand Name : LH-8
Molecule Type : Small molecule
Upfront Cash : Not Applicable
June 19, 2023
Lead Product(s) : Coacillium
Therapeutic Area : Dermatology
Highest Development Status : Phase II/ Phase III
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Coacillium
Therapeutic Area : Dermatology
Study Phase : Phase II/ Phase III
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : LH-8 (coacillium) is an investigational topical botanical drug. Drug interrupts the immuno-inflammatory reactions and their deleterious consequences on hair follicles and adjacent dermal tissues via a pleiotropic mechanism.
Brand Name : LH-8
Molecule Type : Small molecule
Upfront Cash : Not Applicable
January 06, 2023
Lead Product(s) : Coacillium
Therapeutic Area : Dermatology
Highest Development Status : Phase II/ Phase III
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
LOOKING FOR A SUPPLIER?